Baxter licensing of Innocoll gentamicin implant
Executive Summary
Baxter will have exclusive rights in the U.S. to market and distribute Innocoll's gentamicin surgical implant - a biodegradable, leave-behind antibiotic surgical sponge used as an add-on therapy for prevention and treatment of surgical site infections. The product will be regulated as a drug and will be reviewed by CDER, according to the firm. Under the terms of its licensing agreement with Innocoll, Baxter will pay a licensing fee and will make contingent clinical, regulatory and commercial milestone payments; Innocoll will manufacture and supply product, as well as shepherding Gentamicin through the regulatory process. The product is already approved for use in other parts of the world
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.